News | Magnetic Resonance Imaging (MRI) | August 01, 2019 | Jeff Zagoudis, Associate Editor

Draft guidance document, available for public comment for 60 days, provides suggested standards for testing and labeling of medical devices meant to function in an MRI environment

FDA Issues Draft Guidance on Medical Device Safety in MRI Environment

August 1, 2019 — The U.S. Food and Drug Administration (FDA) issued a new draft guidance titled Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment.

The MR environment presents unique safety hazards for patients and other persons with medical devices near or inside an MR system. This draft guidance, when finalized, is intended to:

  • Provide recommendations on testing for assessing the safety and compatibility of medical devices in the MR environment;

  • Identify test methods that address specific hazards and provide recommended format for MRI Safety Information in medical device labeling; and

  • Submit comments on the draft guidance.

According to the FDA, the guidance document “applies to all implanted medical devices, external medical devices that are fastened to or carried by a patient, and all medical devices that are intended to enter the MR environment.” Contents include recommendations on MR safety and compatibility assessments, as well as key information the agency says should be included in any FDA submissions for the affected devices. The guidance does not apply to the MRI scanner systems themselves. 

In the document, the FDA recommends that the safety and performance of a medical device should be assessed for all of the magnetic field strengths to which that device may potentially be exposed. Some of the potential safety issues covered in the document include: 

  • Magnetically induced displacement force and/or torque (unwanted movement of the device caused by the magnetic field); 

  • Heating of the medical device and/or surrounding tissue, by radiofrequency (RF) induction or switching magnetic field gradients;

  • Gradient induced vibration of the medical device;

  • Unintended stimulation of the device by switching gradient pulses;

  • Medical device malfunction; and

  • Image artifacts.

The FDA explains that all devices should be labeled as either MR-conditional (demonstrated safety in the MR environment within defined conditions), MR safe (poses no known hazards resulting from exposure to any MR environment) or MR unsafe (poses unacceptable risks to the patient,medical staff or other persons within the MR environment). 

This draft guidance will be open for public comments for 60 days at www.Regulations.gov under docket number FDA-2019-D-2837.

Read the full draft guidance document.

For more information: www.fda.gov

Related MRI Safety Content

Closing the Loopholes in MRI Safety

VIDEO: New App Improves MRI Safety For Implantable Devices

The Changing Relationship Between MRIs and Pacemakers

How To Manage Risk in the MR Suite


Related Content

News | Radiology Business

April 4, 2024 — FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging ...

Time April 04, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | FDA

March 27, 2024 — SyntheticMR announced that its next-generation imaging solution, SyMRI 3D, has received FDA 510(k) ...

Time March 27, 2024
arrow
News | Artificial Intelligence

March 1, 2024 — Royal Philips, a global leader in health technology, and magnetic resonance imaging (MRI) software ...

Time March 01, 2024
arrow
News | Cardiac Imaging

February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL) may ...

Time February 12, 2024
arrow
News | Radiology Business

January 25, 2024 — Esaote Group, a leading Italian innovator in medical imaging, today unveiled its new brand identity ...

Time January 25, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
News | Artificial Intelligence

December 22, 2023 — Quibim, a company pioneering imaging biomarkers for Precision Medicine that has created AI-based ...

Time December 22, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

December 20, 2023 — Terran Biosciences, Inc., a biotech platform company developing therapeutics and technologies for ...

Time December 20, 2023
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
Subscribe Now